Home | flowbone

Home: Welcome

Home: About Us

Clinical Problem

500 million people worldwide suffer from osteoporosis, a bone disease characterized by a decrease in bone mass and a deterioration of the bone microarchitecture resulting in an increased fracture risk.

10 million hip fractures occur worldwideevery year. These fractures are devastating: 20% of patients die within a year, 15% end up in nursing home, and 30% require assistance. All together, it costs $500 billion to healthcare systems.

These figures are expected to double by 2050 with populations ageing.

Since drug therapies have limited efficacy in preventing these hip fractures, new targeted solutions are urgently needed.

Home: Our Technology

Our Solution

flowbone provides a first-in-class injectable bioactive hydrogel platform for targeted hip fracture prevention.

Unique Mode of Action

Once in place, the gel initiates the deposition of the body's own minerals and rapidly turns into strong, viable bone

Compliance with Bone Biology

No foreign material, no interference with bone vascularization and biomechanics

Minimal Invasiveness

The gel is injected with a cannula into bone regions at hight risk of fracture

flowbone Ltd. was created in July 2020 as spin-off of the at the Laboratory of Biomechanical Orthopedics at the Swiss Federal Institute of Technology Lausanne (EPFL). It is headquartered at EPFL Innovation Park (canton Vaud, Switzerland).

At flowbone, we aim for a world where everybody can enjoy a high level of independence and quality of life, free from the devastating impact of hip fractures.

All our products are still under development and not available on the market.